ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.74
0.00%
US Tech 100
19,034.80
-0.18%
S&P 500
5,433.74
0.23%
US Dollar vs CAD
1.37585
0.11%
Bitcoin
67,074.30
0.48%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Celldex Therapeutics Inc (CLDX)

  7. Celldex Therapeutics Inc (CLDX) News

CLDX

Celldex Therapeutics (CLDX)

Celldex Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CLDX
DateTimeSourceHeadlineSymbolCompany
06/14/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLDXCelldex Therapeutics Inc
06/13/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
06/11/20243:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
06/11/20243:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
06/07/20244:23PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
06/07/20243:57PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
06/07/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
06/05/20243:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
06/05/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
06/05/20243:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
06/04/20243:01PMGlobeNewswire Inc.Celldex Therapeutics to Present at Jefferies Healthcare ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
06/03/20244:51PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
06/03/20244:14PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
06/03/20243:06PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
06/03/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
06/03/20243:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
06/03/20243:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
06/02/20248:01AMGlobeNewswire Inc.Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024NASDAQ:CLDXCelldex Therapeutics Inc
05/30/20245:05PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
05/30/20245:01PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
05/30/20244:47PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
05/30/20242:20PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CLDXCelldex Therapeutics Inc
05/15/20247:01AMGlobeNewswire Inc.Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo NodularisNASDAQ:CLDXCelldex Therapeutics Inc
05/06/20243:07PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CLDXCelldex Therapeutics Inc
05/06/20243:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CLDXCelldex Therapeutics Inc
05/06/20243:01PMGlobeNewswire Inc.Celldex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:CLDXCelldex Therapeutics Inc
04/17/20247:01AMGlobeNewswire Inc.Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible UrticariaNASDAQ:CLDXCelldex Therapeutics Inc
03/08/20246:00AMGlobeNewswire Inc.Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
03/05/20249:30AMGlobeNewswire Inc.Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:CLDXCelldex Therapeutics Inc
03/05/20249:10AMGlobeNewswire Inc.Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:CLDXCelldex Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CLDX

Your Recent History

AMEX
BURU
Nuburu
USOTC
QSEP
QS Energy (PK)
USOTC
NLST
Netlist (QB)
USOTC
GTVH
Golden Triangle Ventures (PK)
USOTC
MWWC
Marketing Worldwide (PK)
NASDAQ
TSLA
Tesla
USOTC
PHIL
PHI (PK)
USOTC
KEGS
1812 Brewing (PK)
USOTC
RDGL
Vivos (QB)
USOTC
PPCB
Propanc Biopharma (PK)
USOTC
VPLM
Voip Pal Com (QB)
USOTC
RSPI
RespireRx Pharmaceuticals (PK)
USOTC
IQST
iQSTEL (QX)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
CGAC
Code Green Apparel (PK)
USOTC
CYDY
CytoDyn (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved